Prepooled cryoprecipitate for treatment of hemophilia A. Transfusion 1983;23(3):265-7
Date
05/01/1983Pubmed ID
6407160DOI
10.1046/j.1537-2995.1983.23383224913.xScopus ID
2-s2.0-0020527831 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
Lyophilized factor VIII concentrates, because of their convenience, are the most commonly used products for providing antihemophilic factor to patients with hemophilia A. Heightened concerns about associated complications indicate that cryoprecipitate usage will increase in the immediate future. We present a protocol for making cryoprecipitate more usable by "prepooling" individual units of cryoprecipitate in an "open" system. Our experience indicates this approach is safe, effective and acceptable to patients, including those on home therapy programs.
Author List
Menitove JE, Spero JA, Richards WA, Lewis JH, Montgomery RR, Gill JC, Hasiba U, Wheeler DV, Sherwin JA, Russell-Vaskov S, Marlar RA, Maxwell NG, Aster RHAuthor
Robert R. Montgomery MD Emeritus Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Factor VIIIFreeze Drying
Hemophilia A
Humans
